MedTrace Logo

Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.

NCT03644329 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-08-23

No results posted yet for this study

Summary

This study intends to evaluate the impact of resistance training variable manipulation (intensity and volume) on body composition, fatigability and functional capacity in postmenopausal breast cancer survivors.

Conditions

  • Breast Cancer Survivors
  • Postmenopause

Interventions

OTHER

Control group

The volunteers will not performed the interventions.

OTHER

Lower-load resistance training (LL)

The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

OTHER

Higher-load resistance training (HL)

The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

OTHER

Higher-volume resistance training (HV)

The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

Sponsors & Collaborators

  • Universidade Federal do Triangulo Mineiro

    lead OTHER

Principal Investigators

  • Fábio L Orsatti, PhD · Federal University of Triângulo Mineiro

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-13
Primary Completion
2018-11-10
Completion
2019-12-20

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644329 on ClinicalTrials.gov